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ABSTRACT
Background. The obective of this study was to perform a cost-
effectiveness analysis comparing intermittent with continuous
renal replacement therapy (IRRT versus CRRT) as initial therapy
for acute kidney injury (AKI) in the intensive care unit (ICU).
Methods. Assuming some patients would potentially be eli-
gible for either modality, we modeled life year gained, the
quality-adjusted life years (QALYs) and healthcare costs for a
cohort of 1000 IRRT patients and a cohort of 1000 CRRT
patients. We used a 1-year, 5-year and a lifetime horizon.
A Markov model with two health states for AKI survivors was
designed: dialysis dependence and dialysis independence. We
applied Weibull regression from published estimates to ﬁt sur-
vival curves for CRRT and IRRT patients and to ﬁt the propor-
tion of dialysis dependence among CRRT and IRRT survivors.
We then applied a risk ratio reported in a large retrospective
cohort study to the ﬁtted CRRT estimates in order to deter-
mine the proportion of dialysis dependence for IRRT survi-
vors. We conducted sensitivity analyses based on a range of
differences for daily implementation cost between CRRT and
IRRT (base case: CRRT day $632 more expensive than IRRT
day; range from $200 to $1000) and a range of risk ratios for
dialysis dependence for CRRT as compared with IRRT (from
0.65 to 0.95; base case: 0.80).
Results. Continuous renal replacement therapy was associated
with a marginally greater gain in QALY as compared with
IRRT (1.093 versus 1.078). Despite higher upfront costs for
CRRT in the ICU ($4046 for CRRT versus $1423 for IRRT in
average), the 5-year total cost including the cost of dialysis
dependence was lower for CRRT ($37 780 for CRRT versus
$39 448 for IRRT on average). The base case incremental cost-
effectiveness analysis showed that CRRT dominated IRRT. This
dominance was conﬁrmed by extensive sensitivity analysis.
Conclusions. Initial CRRT is cost-effective compared with
initial IRRT by reducing the rate of long-term dialysis depend-
ence among critically ill AKI survivors.
Keywords: acute kidney injury, dialysis dependence, economic
analysis
INTRODUCTION
Acute kidney injury (AKI) is a common condition among crit-
ically ill patients in the intensive care unit (ICU). Acute
kidney injury results in rapid loss of kidney function and
worsens the patient’s prognosis. When severe, AKI may neces-
sitate the provision of renal replacement therapy (RRT); RRT
can be applied through two main modalities: continuous RRT
(CRRT) or intermittent RRT (IRRT). Both modalities provide
satisfactory metabolic control and neither has been found su-
perior in terms of survival [1–4]. However, among those who
survive critical illness requiring RRT, failure to recover kidney
function and progression to end-stage kidney disease (ESKD)
leading to dialysis dependence remains a signiﬁcant medical
and economic issue [5].
A recent systematic review and meta-analysis suggested
that among AKI survivors, initial treatment with IRRT might© The Author 2014. Published by Oxford University Press on behalf of ERA-
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be associated with higher rates of dialysis dependence than
initial CRRT [6]. Pooled analyses from seven randomized
controlled trials comparing 240 IRRT patients with 232 CRRT
patients did not show a statistically signiﬁcant difference in
the risk of dialysis dependence between IRRT and CRRT.
However, the point estimate was in the direction of better long-
term renal outcomes with CRRT (relative risk 1.15 [95% CI:
0.78–1.68]). In addition, pooled analyses from 16 observational
studies enrolling 1476 IRRT patients and 2023 CRRT patients
demonstrated a signiﬁcantly higher rate of dialysis dependence
among survivors who initially received IRRT as compared with
CRRT (relative risk 1.99 [95% CI: 1.53–2.59]) [6].
These results were conﬁrmed in a large retrospective cohort
study including 2315 CRRT recipients of whom 2004 (87%)
were 1 : 1 matched to 2004 IRRT recipients [7]. The matching
was comprehensive and based on the history of chronic kidney
disease, receipt of mechanical ventilation within 7 days of the
initiation of RRT and logit of the propensity score for receipt
of CRRT (within ±0.2 SD). This study also showed that the
risk of chronic dialysis was signiﬁcantly lower among patients
who initially received CRRT versus IRRT (hazard ratio 0.75
[95% CI: 0.62–0.87]) [7].
Based on these recent ﬁndings, we hypothesized that initial
CRRT might be economically superior compared with IRRT
and performed a cost-effectiveness analysis of CRRT versus
IRRT in critically ill AKI patients.
MATERIALS AND METHODS
This study followed the CHEERS statement for reporting
economic evaluation [8].
Decision problem
We assumed a cohort of AKI patients who would potential-
ly be eligible for either IRRT or CRRT in the ICU setting. We
then modeled potential health gains and cost savings, compar-
ing patients receiving IRRT as the initial modality with those
receiving CRRT as the initial modality, all else being the same.
Decision analytic model
Using Microsoft Excel, we designed a decision analytic
Markov model. A Markov model is a recursive modeling ap-
proach that spreads a cohort of patients through a series of
transition probabilities across multiple health states [9, 10].
Markov models are used to project the outcomes associated
with speciﬁc treatment options. Health outcomes and health-
care costs are accumulated cyclically as the cohort evolves over
time through the different health states. Our model had two
health states for AKI survivors in the ICU (CRRT and IRRT)
and two health states for AKI survivors discharged from the
hospital (DD: dialysis dependence and DI: dialysis independ-
ence) (Figure 1). Daily cycle was used over the 5 ﬁrst years
after RRT initiation in the ICU and yearly cycle afterward.
Health outcomes were expressed in terms of life year gained
(LYG) and quality-adjusted life years (QALYs). Costs encom-
passed direct medical costs from a US third-party public payer
perspective. Health outcomes and healthcare costs were simu-
lated and averaged for a cohort of 1000 patients initiated on
CRRT and a cohort of 1000 patients initiated on IRRT. Dis-
count rate was set at 3% per annum.
Survival
As there is no evidence of survival differences between
CRRT and IRRT [1–4], we stipulated the same survival
pattern would apply for both initial CRRT and IRRT.
F IGURE 1 : Schematic representation of the Markov model. When AKI occurs in the ICU, patients are initiated on CRRT or IRRT. The ICU
and hospital lengths of stay are supposed to be the same between both modalities. Continuous renal replacement therapy and IRRT patients can
be discharged dialysis dependent or independent. The model assumed that once patients become dialysis dependent, they cannot recover their
renal function and can only remain dialysis dependent or die.
O
R
IG
IN
A
L
A
R
T
IC
L
E
E c o n o m i c s o f d i a l y s i s d e p e n d e n c e i n A K I 55
Transition probabilities toward death were not assumed con-
stant over time. They were modeled with a single survival
curve for both modalities using a Weibull regression on three
survival proportions, assumed to be 60% at discharge [11, 12],
46% at Day 60 [11, 12] and 37% at Day 180 [13] (Table 1 and
Figure 2A).
Dialysis independence among AKI survivors
For both initial CRRT and IRRT, the time-dependent pro-
portion of AKI survivors becoming dialysis dependent was
ﬁtted from the study by Wald et al. [7] using a Weibull regres-
sion on two data points: at Day 90 and at the median follow-up
of 3 years, i.e. Day 1095 (Table 1 and Figure 1B). Continuous
renal replacement therapy dialysis independence estimates
were then obtained by applying a risk ratio to IRRT estimates.
In the base case, this risk ratio was ∼0.80 (16.4/20.8% = 0.79
and 21.7/26.6 = 0.82). Wald et al. reported a hazard ratio of
0.75 (95% CI: 0.65–0.87) [7].
Switch from initial CRRT to IRRT over the ICU stay
We accounted for the fact that it is relatively common prac-
tice to switch AKI patients initiated on CRRT to IRRT as their
Table 1. Continuous renal replacement therapy and IRRT input values
CRRT IRRT Reference
ICU stay
ICU LoS (days) 12 12 [13]
RRT duration (days) 7 7 [13]
Switch from CRRT to IRRT (%) 30 — Assumption
Survival (all cause death)
Discharged alive from ICU (%) 60.0 60.0 [11, 12]
Alive at 60 days (%) 46.0 46.0 [11,12]
Alive at 180 days (%) 37.0 37.0 [13]
DD among AKI survivorsa
DD at 90 days (%) 16.4 20.8 [7]
DD at 3 years (%) 21.7 26.6 [7]
Cost of implementing RRT
Acute RRT cost/day $858 $226 [14, 15]
Health utilities
ICU stay 0.13 0.13 [16]
DI 0.84 0.84 [17]
DD 0.62 0.62 [17]
Healthcare costs
DI cost/day $31 $31 [5]
DD cost/day $211 $211 [5]
LoS, length of stay; ICU, intensive care unit; CRRT/IRRT, continuous/intermittent renal
replacement therapy; DI, dialysis independence; DD, dialysis dependence.
aThis corresponds to a risk ratio of ∼0.80 for the base case (16.4/20.8% = 0.79 and
21.7/26.6% = 0.82).
F IGURE 2 : Survival and cumulative risk of dialysis dependence assumptions per initial RRT modality in the ICU. DD, dialysis dependence.
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hemodynamic status evolves favorably [11]. In doing so, we
assumed that switches from CRRT to IRRT will not alter the
subsequent risk of dialysis dependence but would reduce the
RRT daily implementation cost. In other words, initial CRRT
patients switched to IRRT were applied the initial CRRT out-
comes. Indeed, most of the studies retrieved in the literature
compared initial RRT modalities only. We varied this propor-
tion of CRRT patients being switched to IRRT over the ICU
stay from 0 to 60%, with a base case at 30% and assuming a
constant daily rate of switch over the ICU stay.
Health utility and cost
All health state utilities and costs were assumed to be the
same between CRRT and IRRT except the daily cost of the
RRT implementation in the ICU. Therefore, the model only
accounted for the cost of implementing CRRT or IRRT in the
ICU, the daily cost of dialysis independence and the daily cost
of dialysis dependence in the outpatient setting. Health util-
ities and costs assigned to each health state were taken from lit-
erature [5, 14–17] (Table 1). All costs were inﬂated to 2013
$US using the Consumer Price Index for Medical Care Ser-
vices from the US Bureau of Labor Statistics [18].
Base case analysis
Base case values are summarized in Tables 1 and 2. All
values were the same for both modalities, CRRT and IRRT,
except the daily implementation cost [14, 15] and the cumula-
tive risk for dialysis dependence among survivors (Figure 2B)
[7]. The daily cost of CRRT was set at $858, and the daily cost
of IRRT at $226 based on estimates from Manns et al. [14]
converted and inﬂated to US$ 2013. For the cost of CRRT, we
used conservatively the high estimate reported by Manns et al.
in lieu of the low one ($586). The resulting cost difference of
$632 between the two RRT modalities falls within the inter-
quartile range of the cost difference reported by Srisawat et al.
from $134 to $950 with a median at $331 ($US 2013) [15]. In
the base case analysis, we used a 5-year time horizon to
compute the ICER of initial CRRT versus initial IRRT and to
compare the 5-year cumulative total cost and cost of dialysis
dependence between the two initial RRT modalities.
Sensitivity analysis
First, we conducted a series of one-way sensitivity analysis
and presented results as Tornado diagram. Second, we ran a
two-way deterministic sensitivity analysis by varying the two
key model parameters distinguishing CRRT from IRRT: the
daily implementation cost difference and the cumulative risk
of dialysis dependence. The daily implementation cost differ-
ence between CRRT and IRRT varied from $200 to $1000
(base case at $632) and the risk ratio for dialysis dependence
between CRRT and IRRT varied from 0.65 to 0.95 (base case
around 0.80). Finally, we re-ran all analyses twice, with a
1-year time horizon and a lifetime time horizon.
RESULTS
Base case analysis
Table 2 displays the undiscounted 5-year results for the
base case analysis. Continuous renal replacement therapy was
associated with a marginally greater gain in QALY as com-
pared with IRRT (1.093 versus 1.078). Despite higher upfront
average costs for CRRT patients in the ICU ($4046 for CRRT
versus $1423 for IRRT), the 5-year total cost including the cost
of dialysis dependence was lower for a CRRT patient ($37 780
for CRRT versus $39 448 for IRRT on average).
The 5-year undiscounted cumulative total cost of the initial
IRRT cohort exceeded that of the initial CRRT cohort within
2-year post-RRT initiation (Figure 3). The cost of dialysis de-
pendence in the initial CRRT cohort was constantly lower
than that for the initial IRRT cohort (Figure 3).
The ICER of CRRT versus IRRT was negative (−$116 121),
meaning that CRRT dominated IRRT (QALYCRRT > QALYIRRT
and CostCRRT < CostIRRT) and was thus cost-saving (Table 2).
This dominance was conﬁrmed in the 5-year discounted ana-
lysis (ICER =−$106 527) and the lifetime discounted analysis
(ICER =−$196 956) but not in the 1-year analysis (ICER =
$400 701).
Sensitivity analysis
Figure 4 shows the tornado diagrams obtained by varying
seven parameters from low to high base. The risk ratio of dia-
lysis dependence of initial CRRT as compared with initial
IRRT and the health utility attributed to the dialysis independ-
ence state contributed the most to the variability of the ICER.
The latter is explained by the fact that as this utility (low case
at 0.67) gets closer to one of the dialysis dependence states
(base case at 0.62), the denominator of the ICER approaches
zero (i.e. nearly identical QALY gained between initial CRRT
and initial IRRT). The other key parameter contributing the
most to the variability of the ICER was the daily cost difference
between CRRT and IRRT. The risk of dialysis dependence was
the only parameter that noticeably resulted in an ICER of >0
(QALYCRRT > QALYIRRT and CostCRRT > CostIRRT).
Figure 5 presents a two-way sensitivity analysis, varying
the risk ratio for dialysis dependence and the daily
Table 2. Five-year cost-effectiveness analysis of initial CRRT versus initial
IRRT (undiscounted)
CRRT IRRT
Health outcomes
LYG 1.387 1.387
QALYs 1.093 1.078
Costs
RRT modality $4046 $1423
Dialysis independence (DI) $12 380 $11 642
Dialysis dependence (DD) $21 354 $26 383
Total $37 780 $39 448
Cost-effectiveness analysis
Cost/LYG $27 248 $28 451
Cost/QALYs $34 578 $36 586
ICER CRRT versus IRRTa −$116 121 —
‘(CRRT dominates)’
aICER: incremental cost-effectiveness ratio = (CostCRRT –CostIRRT)/
(QALYCRRT –QALYIRRT).
CRRT dominates IRRT as QALYCRRT > QALYIRRT and CostCRRT < CostIRRT.
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implementation cost at the same time. Initial CRRT was
predominantly cost-effective as compared with initial IRRT at
the generally prevailing $50 000/QALY threshold.
DISCUSSION
Initial treatment with CRRT is cost-effective when compared
with IRRT among critically ill patients with AKI by reducing
the costs associated with the greater rate of long-term dialysis
dependence. To our knowledge, this is the ﬁrst economic ana-
lysis focusing on dialysis dependence among AKI survivors. In
the light of a recent large observational cohort study [7], con-
ﬁrming previous meta-analytic ﬁndings [6], we demonstrated
through a comprehensive model the potential economic ad-
vantage of CRRT compared with IRRT, despite the higher
CRRT upfront cost in the ICU.
Our analysis contradicts previous economic ﬁndings. Both
Klarenbach et al. [17] and De Smedt et al. [16] concluded that
CRRT presented neither health nor economic advantage over
IRRT. Using a lifetime horizon, Klarenbach et al. reported that
CRRT resulted in equivalent health outcomes with IRRT but
was CAN$3679 (≈$3309) more costly due to the higher direct
costs of providing CRRT [17]. Using a 2-year life time
horizon, De Smedt et al. reported that the supplementary cost
per additional QALY associated with CRRT reached 114 012
€/QALY (≈$156 600), far exceeding the willingness to pay a
threshold of 30 000 €/QALY (≈$41 200) [16].
In contrast, we found that CRRT dominated IRRT. In our
analysis, only the 1-year time horizon yielded an ICER above
the 50 000 $/QALY threshold, but both the 5-year and the life-
time horizons resulted in CRRT dominance over IRRT. At
400 701 $/QALY in the 1-year analysis, the ICER reached the
50 000 $/QALY threshold a Day 821 (2.2 years) and then
became negative from Day 990 (2.7 years) indicating CRRT
dominance over IRRT. Continuous renal replacement therapy
was associated with a marginally greater gain in QALYs
as compared with IRRT. This was due to the lower dialysis
F IGURE 3 : Five-year cumulative cost difference between initial CRRT and initial IRRT (undiscounted).
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dependence among survivors. In addition, and despite higher
ICU costs for CRRT, the cumulative total cost including the
cost of dialysis dependence was lower for CRRT.
Our model explicitly includes the effect of both initial mo-
dalities on renal recovery among survivors. To model the risk
of chronic dialysis between the two initial modalities, we used
latest observational estimates as obtained by robust propensity
score matching methodology on a large sample of patients [7].
This research conﬁrmed previous meta-analysis ﬁndings [6]
and consolidated the fact that initial CRRT may actually lead
F IGURE 4 : One-way deterministic sensitivity analysis (Tornado diagram).
F IGURE 5 : Two-way deterministic sensitivity analysis.
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to less dialysis dependence as compared with initial IRRT. We
translated this important clinical outcome into an economic
assessment and reported an economic advantage of initial
CRRT over IRRT.
Several reasons have led us to use the large observational
study [7] instead of the meta-analysis [6] to document the
risk of chronic dialysis between initial IRRT and initial CRRT
in our model. First, the study is to our knowledge the only
original study addressing the issue with direct data rather than
derived data. Second, the study is of high quality, using
propensity matching for treatment allocation and running
multiple sensitivity analyses to evaluate the robustness of the
data. Propensity matching for treatment allocation is precisely
meant to minimize the risk of allocation bias, one of the prin-
cipal limitations of observational studies on which the meta-
analysis is largely based. Third, the effect seen in the large
observational study is less than that in the meta-analysis,
allowing our analysis to be more conservative. Finally, the
meta-analysis included only papers published before 2012 and
thus omitted the study by Wald et al., [7] which is by far the
largest and most recent study published to date on the topic.
Our model has a number of limitations and assumptions
that should be discussed. Our analysis assumed a cohort of
AKI patients who would potentially be eligible for either IRRT
or CRRT in the ICU. As such, our ﬁndings do not apply to
those clinical circumstances where a speciﬁc RRT modality is
particularly recommended or preferable. This may limit the
generalizability of our ﬁndings.
In modeling the post-AKI dialysis-dependent and dialysis-
independent patients’ quality-of-life and costs, we used as sur-
rogates ESKD patients and non-ESKD patients who otherwise
share similar characteristics. We have used these surrogates
to compute the ongoing costs of dialysis dependence and
independence. However, post-AKI patients may actually have
worse quality-of-life than standard ESKD patients [19]. There-
fore, they may possibly have higher medical costs as well.
For reasons of clarity, we only accounted for the costs
driven by the choice of RRT in the ICU and by the subsequent
daily medical costs for dialysis dependence and dialysis inde-
pendence for outpatients, as all other costs were assumed to be
the same between both modalities. As health economics inves-
tigates the incremental ratio between multiple strategies, those
costs were not indispensable. Their inclusion in the ICER
computation would not have changed the conclusion of the
model.
With regard to the cost difference between CRRT and
IRRT in the ICU, we used the estimates reported by Srisawat
et al. from the BEST Kidney Investigators, probably one of the
most complete and global cost assessments of acute RRT [15].
A number of other cost studies have been done over the years,
but they were all consistent with the BEST study, as summar-
ized elsewhere [20]. Costs of chronic dialysis for outpatients
encompassed only direct medical costs from an US third-party
public payer perspective. It should be noted that these costs
are similar to and consistent with public sector costs in
Germany [21] and in Australia [22].
Patients initiated on CRRT can be switched to IRRT when
clinical conditions permit, in particular once patients become
hemodynamically stable while acute RRT is still required.
Therefore, switching from initial CRRT to IRRT during the
ICU stay is relatively common in settings where both modal-
ities are available. As there is a paucity of data on that speciﬁc
issue, we modeled the possibility of switch from initial CRRT
to IRRT over the ICU stay as sensitivity analysis. We applied
the same renal outcome of those patients receiving initial
CRRT only to those initial CRRT patients being switched to
IRRT. In effect, the results presented in the literature com-
pared initial modalities only. This has only enhanced the eco-
nomic attractiveness of CRRT versus IRRT, proving similar
renal and health outcomes but at a slightly decreased cost of
acute RRT, IRRT being less expensive than CRRT.
We assumed a constant daily rate of switch from CRRT to
IRRT but varying the overall switch rate during the ICU stay
from 0 to 60%. In all likelihood, the switch rate from CRRT to
IRRT during the ICU stay greatly depends on the local setting
as well as the availability of modalities and staff. In some coun-
tries, no CRRT patient will be switched to IRRT before the
patient is ready for discharge whereas in others, CRRT patients
will be transitioned to IRRT when hemodynamically stable,
generally close to discharge but not necessarily. The data from
the ATN trial suggest switching rates from initial CRRT to
IRRT between 20 and 40% [23].
Our ﬁndings put a ﬁgure on recent observational studies
that showed the potential protective effect of initial CRRT
against dialysis dependence among AKI survivors. We also
echo a recent editorial, challenging the economic case for
using initial conventional IRRT in the ICU [24]. We show that
CRRT might be less costly in the long run by diminishing the
necessity of chronic dialysis among survivors. This also trans-
lates into quality-of-life beneﬁts for survivors knowing the
psychosocial burden of chronic dialysis.
CONCLUSIONS
In conclusion, our analysis suggests that initial CRRT is cost-
effective compared with initial IRRT by reducing the rate of
long-term dialysis dependence among critically ill AKI survi-
vors. Knowledge of such economic advantages has implica-
tions for public health planning, resource allocation and
physician choices.
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